MedDataX Logo

The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy

NCT ID: NCT05924061

Last Updated: 2023-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

156 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the investigator aim was to compare Cathepsin B and Pentraxin 3 levels measured from maternal serum of pregnant women diagnosed with preeclampsia in the second trimester, the effects of these levels on maternal/ fetal outcomes and the composite results of Cathepsin B and Pentraxin 3 levels alone or together and contribute to the literature in this area.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective case-control study was conducted between 1 January 2022 and 31 December 2022 at Bursa Yuksek Ihtisas Training and Research Hospital. The study was conducted with pregnant women between ages of 18-45 who were diagnosed with preeclampsia in the second trimester. This study was conducted with total 156 pregnant women. participants were grouped according to the presence of preeclampsia; Group1: Patients diagnosed with preeclampsia between 20-28 weeks (study group) (n:78) , Group 2: Healthy pregnant women between 20-28 weeks without a diagnosis of preeclampsia ( control group) (n:78) . As soon as preeclampsia is diagnosed and before any treatment was started, maternal serum samples were collected in the Cathepsin B and Pentraxin 3 kit in amounts suitable for the study. The samples obtained were kept in biochemistry laboratory at -80 degrees until the study was conducted. After all samples were collected, Cathepsin B and Pentraxin 3 values were measured by ELISA method.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia Cathepsin B Level Pentraxin 3 Level

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

second trimester preeclampsia pentraxin 3 Cathepsin B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women with preeclampsia between 20-28 weeks (study group)

Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks pregnant women with preeclampsia

Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women

Intervention Type OTHER

The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia

Healthy pregnant women between 20-28 weeks ( control group)

Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks healthy pregnant women ( control group)

Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women

Intervention Type OTHER

The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women

The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton pregnancy
* Pregnant women diagnosed with preeclampsia between 20-28 weeks of gestation
* Healthy pregnant women between 20-28 weeks of gestation who want to be involved in the study.

Exclusion Criteria

* Multiple pregnancies
* Pregnant women who gave birth below 24 weeks of gestation
* Pregnant women diagnosed with other hypertensive diseases of pregnancy other than preeclampsia ( gestational hypertension, chronic hypertension, superimposed hypertension)
* Pregnant women with chromosomal or congenital anomalies in the fetus
* Women with a known infective or autoimmune disease before pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanliurfa Mehmet Akif Inan Education and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nefise Nazlı YENIGUL

Ph.D. Assistant Professor Department of Obstetrics and Gynecology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nefise Nazlı YENIGUL

Bursa, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-KAEK-25 2021/09-09

Identifier Type: -

Identifier Source: org_study_id